ACTH1-24 counteracts the prolactin-releasing effect of an opioid.
The administration of the synthetic and stable opioid peptide[D-Ala2,MePhe4,Met(O)5o1]enkephalin (FK 33-824) at the dose of 0.2 mg/kg i.v. induced a rise in plasma levels of prolactin in the rat, an effect which was prevented by 1 mg/kg i.v. of the opiate antagonist naloxone. A simultaneous i.v. injection of 20 microgram/kg i.v. of ACTH1-24 significantly reduced the prolactin releasing effect of FK 33-824, therefore giving further evidence of an in vivo interaction between ACTH-related peptides and opioid peptides.
D000324:Adrenocorticotropic Hormone / Q000031:analogs & derivatives*; D000818:Animals; D003366:Cosyntropin / Q000494:pharmacology*; D005405:D-Ala(2),MePhe(4),Met(0)-ol-enkephalin; D004723:Endorphins / Q000037:antagonists & inhibitors*; D004745:Enkephalins / Q000037:antagonists & inhibitors*; D008297:Male; D011388:Prolactin / Q000378:metabolism*; D011863:Radioimmunoassay / Q000379:methods; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors
D004723:Endorphins; D004745:Enkephalins; D003366:Cosyntropin; D005405:D-Ala(2),MePhe(4),Met(0)-ol-enkephalin; D000324:Adrenocorticotropic Hormone; D011388:Prolactin